99m-technetium-labelled peptide-HYNIC conjugates: Effects of lipophilicity and stability on biodistribution

Nuclear Medicine and Biology

Volumn 26, Issue 4, 1999, Pages 389-396

  Decristoforo, Clemens ^a   Mather, Stephen J ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Co ligands; HYNIC; Peptides; Pharmacokinetics; Technetium

Indexed keywords

6 HYDRAZINOPYRIDINE 3 CARBOXYLIC ACID; EDETIC ACID; EDETIC ACID DERIVATIVE; HYDRAZINE DERIVATIVE; NICOTINIC ACID DERIVATIVE; SOMATOSTATIN DERIVATIVE; TECHNETIUM 99M; UNCLASSIFIED DRUG; VAPREOTIDE;

ANIMAL EXPERIMENT; ARTICLE; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STABILITY; DRUG UPTAKE; IMAGE QUALITY; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; LIPOPHILICITY; MALE; NONHUMAN; RADIOISOTOPE DISTRIBUTION; RAT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; HYDRAZINES; ISOTOPE LABELING; MALE; NICOTINIC ACIDS; PEPTIDES; PROTEIN BINDING; RATS; RATS, WISTAR; SOLUBILITY; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 0032984811     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(98)00118-8     Document Type: Article

References (20)

1. Abrams M.J., Juweid M., tenKate C.I., Schwartz D.A., Hauser M.M., Gaul F.E., Fuccello A.J., Rubin R.H., Strauss H.W., Fischman A.J. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med. 31:1990;2022-2028.
2. Babich J.W., Fischman A.J. Effect of "co-ligand" on the biodistribution of 99mTc-labeled hydrazino nicotinic acid derivatized chemotactic peptides. Nucl. Med. Biol. 22:1995;25-30.
3. Babich J.W., Graham W., Barrow S.A., Dragotakes S.C., Tomkins R.G., Rubin R.H., Fischman A.J. Technetium-99m-labeled chemotactic peptides Comparison with indium-111-labeled white blood cells for localizing acute bacterial infection in the rabbit . J. Nucl. Med. 34:1993;2176-2181.
4. Barrett J.A., Crocker A.C., Damphousse D.J., Heminway S.J., Liu S., Edwards D.S., Lazewatsky J.L., Kagan M., Mazaika T.J., Carroll T.R. Biological evaluation of thrombus imaging agents utilizing water soluble phosphines and tricine as co-ligands when used to label a hydrazinonicotinamide-modified cyclic glycoprotein Iib/IIIa receptor antagonist with 99mTc. Bioconjugate Chem. 8:1997;155-160.
5. Edwards D.S., Liu S., Barrett J.A., Harris A.R., Looby R.J., Ziegler M.C., Heminway S.J., Carroll T.R. New and veratile ternary ligand system for technetium radiopharmaceuticals Water soluble phosphines and tricine as co-ligands in labeling a hydrazinonicotinamide-modifies cyclic glycoprotein Iib/IIIa receptor antagonist with 99mTc . Bioconjugate Chem. 8:1997;146-154.
6. Fischman A.J., Babich J.W., Strauss H.W. A ticket to ride Peptide radiopharmaceuticals [review] . J. Nucl. Med. 34:1993;2253-2263.
7. Harris T.D., Barrett J.A., Bourque J.P., Carroll T.R., Damphousse P.R., Edwards D.S., Glowacka D., Liu S., Looby R.J., Poirier M.J., Rajopadhye M., Yu K. Design and synthesis of radiolabeled GPIIb/IIIa receptor antagonists as potential thrombus imaging agents [abstract 1005]. J. Nucl. Med. 35:1994;245P.
8. Hnatowich D.J., Mardirossian G., Rusckowski M., Forgarasi M., Virzi F., Winnard P. Directly and indirectly technetium-99m-labeled antibodies A comparison of in vitro and animal in vivo properties . J. Nucl. Med. 34:1993;109-119.
9. Hnatowich D.J., Winnard P., Virzi F., Fogarasi M., Sano T., Smith C.L., Cantor C.R., Rusckowski M. Technetium-99m labeling of DNA oligonucleotides. J. Nucl. Med. 36:1995;2306-2314.
10. Krenning E.P., Kwekkeboom D.J., Bakker W.H., Breeman W.A., Kooij P.P., Oei H.Y., van Hangen M., Postema P.T., de Jong M., Reubi J.C., Visser T.J., Reij A.E.M., Hofland L.J., Koper J.W., Lamberts S.W.J. Somatostatin receptor scintigraphy with [111-In-DTPA-D-Phe] and [123-I-tyr]-octreotide The Rotterdam experience with more than 1000 patients . Eur. J. Nucl. Med. 20:1993;716-731.
11. 99mTc]Tricine: A useful precursor complex for the radiolabelling of hydrazinonicotinate protein conjugates. Bioconjugate Chem. 6, 635-638.
12. 99mTc. Q. J. Nucl. Med. 40:1996;221-233.
13. 99mTc labeling of highly potent small peptides. Bioconjugate Chem. 8:1997;621-636.
14. Liu S., Edwards D.S., Harris A.R. Pyridine analogs as co-ligands for preparation of technetium-99m radiopharmaceuticals [abstract 958]. J. Nucl. Med. 39:1998;215P.
15. Liu S., Edwards D.S., Looby R.J., Harris A.R., Poirier M.J., Barrett J.A., Heminway S.J., Carroll T.R. Labeling a hydrazino nicotinamide-modified cyclic IIb/IIIa receptor antagonist with 99mTc using aminocarboxylates as co-ligands. Bioconjugate Chem. 7:1996;63-71.
16. Mäcke H., Behe M. New octreotide derivatives labelled with technetium-99m [abstract 107]. J. Nucl. Med. 37:1996;29P.
17. Schally A.W. Oncological applications of somatostatin analogues. Cancer Res. 48:1988;6977-6985.
18. Thakur M.L. Radiolabelled peptides Now and the future . Nucl. Med. Commun. 16:1995;724-732.
19. Thakur M.L., Kolan H., Wiaderkiewicz R., Pallela V.R., Duggaraju R., Schally A.V. Radiolabeled somatostatin analogs in prostate cancer. Nucl. Med. Biol. 24:1997;105-113.
20. Virgolini I., Raderer M., Kurtaran A., Angelberger P., Banyai S., Yang Q., Li S., Banyai M., Pidlich J., Niederle B., Scheitaver W., Valent P. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N. Engl. J. Med. 27:1994;1116-1121.